Merck Serono donates €2.8m to EspeRare Foundation

Published: 15-Apr-2013

Foundation will initially investigate rimeporide in Duchenne Muscular Dystrophy (DMD)


Three Merck Serono employees have set up the EspeRare Foundation under the Merck Serono Entrepreneur Partnership Program (EPP).

Merck Serono will donate an initial €2.8m in funding to the new non-profit organisation and transfer the rights to rimeporide, a Merck compound for heart failure. The EspeRare Foundation will investigate this compound in Duchenne Muscular Dystrophy (DMD), a genetic rare disease affecting 1 in every 3,600 males.

‘The EspeRare Foundation is the first initiative of its kind in the framework of the EPP. It is the result of our employees’ determination to develop a unique operating model for the benefit of patients suffering from rare diseases, a field with high unmet needs and hardly no treatments available,’ said François Naef, Chairman of the Board of Directors of Merck Serono. ‘The Foundation will play a central role by pioneering a collaborative system that brings together the right stakeholders to explore the therapeutic value of existing compounds, ultimately accelerating the R&D process in rare diseases.’

The EspeRare Foundation’s mission is to uncover the potential of existing drugs to address severe therapeutic unmet needs in rare diseases, through an established network of patient organisations, pharmaceutical companies, biotechs, regulators and academic institutions.

Our priorities are not determined by commercial incentives or the size of a market, they are solely driven by the medical needs of patients suffering from rare diseases

Caroline Kant, Florence Porte and Béatrice Greco have set up the Foundation. Sharon Terry, President and CEO of Genetic Alliance and an Executive Board Member of the International Rare Disease Research Consortium (IRDiRC), will join the organisation as President.

‘As a non-profit organisation, our priorities are not determined by commercial incentives or the size of a market, they are solely driven by the medical needs of patients suffering from rare diseases and the wealth of good science already available.

‘We strive to apply our patient-centric model and our pharma R&D expertise to advance the discovery of new treatments for these underserved patients,’ said Kant, Executive Director and Co-Founder of the EspeRare Foundation.

Terry added: ‘The International Rare Disease Research Consortium has publicly and boldly declared that we, as a global community, will have 200 new drugs for rare diseases by 2020. The EspeRare Foundation has a great potential to become an important component in the new system that must be built to achieve this goal. The current pharma model needs to be adapted, new pathways are being forged and the Foundation will be a catalyst and incubator for a new way of addressing rare diseases.’

The EspeRare Foundation will be presented to the public and to the international rare diseases community, at the first IRDiRC conference, taking place this week in Dublin, Ireland, on 16–17 April.

The EspeRare Foundation is the seventh organisation to benefit from the support of the Merck Serono EPP. Since 2012, this programme has contributed to the creation of local biotech start-ups (Prexton Therapeutics, Asceneuron, Calypso Biotech) and service companies (Quartz Bio, TQM Insight, Ondaco).

The EspeRare Foundation headquarters will be hosted in Eclosion, a public incubator for life sciences start-ups located in Plan-Les-Ouates, Geneva, Switzerland.

You may also like